A 200-μg, controlled-release misoprostol vaginal insert reduced median time to vaginal delivery by 11.3 hours compared with another prostaglandin, but it also increased the rate of uterine ...

PARSIPPANY, N.J., Oct. 23, 2012 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ...

As the question of mifepristone’s availability in the U.S. is fought out in federal courts, states and health care providers are looking to the only other abortion pill approved for use here and the ...

When people refer to “the abortion pill,” they’re usually talking about mifepristone, the progesterone-inhibiting drug that was developed in France in the 1980s and approved in the U.S. in 2000. This ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Use of misoprostol alone was shown to be effective in ...

In a letter dated Sept. 30, the agency approved an additional generic version of the abortion drug mifepristone, this one by the company Evita Solutions. The company says on its website "we seek to ...

Several states say they are stocking up on medications used to induce abortions as a major abortion pill appears poised to potentially become unavailable in the U.S. New York has become the latest ...

As with other drugs, misoprostol can cause side effects, such as vaginal cramps, diarrhea, and abdominal pain. If you are unable to tolerate side effects from misoprostol, talk with your doctor or ...

Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women Parsippany, NJ, USA, 23 October 2012 – Ferring ...